Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
DOH CL advocates healthy habits to safeguard against liver cancer punto.com.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from punto.com.ph Daily Mail and Mail on Sunday newspapers.
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.